BioSpace News Archive

August has been busy with a flurry of life sciences expansion announcements, particularly in the United States and Canada. Here’s a look at a few companies increasing their presence in the two countries.

A Sackler family heir said in a court appearance that the family, which owns OxyContin drug maker Purdue Pharma, holds a “moral responsibility” to lend its help in combating the U.S. opioid crisis but noted it will not give billions of dollars to a legal settlement unless broad legal protections are provided in exchange.

BioLineRx Ltd. today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.

Northwell Health president and CEO Michael J. Dowling, MSW, will be the keynote speaker for ARUP Laboratories’ inaugural Lab Leadership Symposium, “Creating Connections: Advancing Your Lab’s Value in the Healthcare System,” which will be held Thursday, October 21, 2021, via Zoom.

iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens (“iSpecimen” or the “Company”), today announced it has grown its cancer-related supplier network despite lockdowns, slowdowns, and sustained concern around the COVID-19 pandemic.

To aid in the clinical development of new vaccines and monoclonal antibodies (MAbs) effective against emerging and highly infectious coronavirus variants, Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus particles (RVPs), currently over 65 variants, which enables neutralizing antibodies or serum to be assessed in accordance with recent FDA guidances.

Vigil Neuroscience today announced the completion of a $90 million Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.

Ranok Therapeutics today announced it had secured a $40 million Series B funding round denominated in both U.S. dollars and Chinese yuan.

EQRx today announced the appointment of Richard Buckley as chief corporate affairs officer.

NFlection Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has granted the company orphan drug designation for NFX-179 for the treatment of cutaneous neurofibromatosis type 1.